The Covid-19 pandemic was the biggest biopharma news of 2020. It may be hard to remember now, but in March of last year, biotech indices had quickly nose-dived, along with the broader market, as the reality of the pandemic became apparent. The prevailing financial sentiment was doom and gloom.
Geoff Meyerson co-founded Locust Walk, a Boston-based life sciences consulting firm, on Sept. 15, 2008, the same day that Lehman Brothers filed for bankruptcy and Merrill Lynch sold itself to Bank of America.
Each quarter our team at Locust Walk compiles key statistics and trends on strategic transactions and financings. Our 2020 Year End Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life science deal landscape.
Following up on our recent white paper, Biopharma’s COVID Capital Comeback, here is a look at the greatest risk facing public biopharma companies — single asset failures — and what they can do during this time of robust capital.
Q3 2020 Report: Global Trends in Biopharma Transactions Each quarter our team at Locust Walk compiles key statistics and trends on strategic
BIO (Biotech Innovation Organization) collected a survey in January of 2020 to better understand the current demographics of biopharma companies. Responses to their questions on representation indicate that the number of women decreases at higher levels.
Biopharma’s COVID Capital Comeback What a difference a few months can make – especially during a pandemic. Heading into 2020,
Heading into 2020, biopharma looked like it would be typecast in its typical election year role: the big business scapegoat for everything that’s wrong in health care. There had been the usual big Phase 3 trial failures.
CATEGORIES News Events Publications ARCHIVE Panel Recording: The Unexpected IPO Boom in Biopharma in Q2 Locust Walk partnered with Applied
Locust Walk is partnering with Applied Molecular Transport, Forma Therapeutics, and Goodwin for a live panel on Thursday, July 23rd from 1-2 pm EST entitled “The Unexpected IPO Boom for Biopharma in Q2.”